Under the terms of the agreement, Hikma will have the exclusive rights to register, distribute and market Zevtera® in all its MENA markets leveraging Hikma’s strong local presence, sales and marketing capabilities and regulatory expertise. Zevtera® has received approvals in 13 European countries and Canada for the treatment of adult patients with community- and hospital-acquired pneumonia (CAP, HAP), excluding ventilator-associated pneumonia (VAP), and has been launched in Germany, France, Italy and the UK.

Mazen Darwazah, Vice-Chairman and CEO of MENA and Emerging Markets said, “Our partnership with Basilea will allow us to bring more innovative anti-infective products to the MENA, enhancing our growing portfolio of differentiated high value products and reinforcing our commitment to increasing patients’ access to high-quality medicines.”